Abstract 49P
Background
Leptin is produced by adipose tissue of breast and is overexpressed in Breast cancer. Association of leptin gene (LEP) and leptin receptor gene (LEPR) polymorphisms with Breast cancer are inconsistent. Only a very few studies have examined this biochemical and genetic variables so we planned to investigate this association and its impact on leptin level and disease characteristics.
Methods
Study included 70 females (40 women with pathological prove of invasive Breast cancer patients and 30 controls). Staging was done according to the American Joint Committee on Cancer 8th edition. LEP and LEPR polymorphisms were estimated by real time PCR. Serum leptin was measured by ELISA.
Results
Both LEPR rs 1137101 and LEP rs 7799039 increase risk of breast cancer where GG genotype and G allele frequencies of LEPR rs 1137101 were significantly higher in patients than control [52.5% vs 16.7% and 68.8% vs 36.7%] (p = 0.002) and (p < 0.001) respectively. GG genotype increase risk of BC with [OR 9.1: 95% CI 2.30-35.94] while G allele predispose to disease with [OR 3.8: 95% CI 1.87 – 7.70]. Furthermore, LEP rs 7799039 A allele was markedly elevated in patients (61.2%) than healthy ones (43.3%) (p = 0.037) with [OR 2.06: 95% CI 1.05 – 4.08]. Leptin levels were markedly elevated than healthy ones (p < 0.001).
Conclusions
Results clarified interesting relation of circulating leptin level and LEP and LEPR polymorphisms with predicting Breast cancer that may be implicated in pathogenesis of disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Menoufia University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
Presenter: Xiaomei Liu
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract
339TiP - PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract